|
Price: $43.4700
$-0.39 
-0.889%
|
| Day's High:
| $43.65999984741211
| Week Perf:
| 0.42 %
|
| Day's Low: |
$ 42.79 |
30 Day Perf: |
4.17 % |
| Volume (M): |
1,922,186 |
52 Wk High: |
$ 57.82 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$43.42 |
| Open: |
$43.19 |
52 Wk Low: |
$32.53 |
|
|
| Market Capitalization (Millions $) |
9,515 |
| Shares
Outstanding (Millions) |
219 |
| Employees |
5,700 |
| Revenues (TTM) (Millions $) |
2,035 |
| Net Income (TTM) (Millions $) |
425 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
6 |
Business Description
Qiagen N.V. is a biotech company that provides molecular diagnostics and life science research services.
The company develops and markets sample and assay technologies, including PCR, Sequencing, and Genomics, to customers in the academic research, pharma and biotech, healthcare, and environmental testing industries.
Qiagen Nv's products and services enable scientists to extract and process DNA, RNA, and other types of biological samples, perform gene expression analysis, and identify biomarkers for disease diagnosis and therapy.
Qiagen Nv was founded in 1984 and is headquartered in Venlo, Netherlands, with operations across the world.
Company Address: Hulsterweg 82 Venlo 5912
Company Phone Number: Stock Exchange / Ticker: NYSE QGEN
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Wed, Oct 29 2025 3:58 PM UTC
QIAGEN Celebrates 4,000th QIAcube Connect Placement, Reinforcing Commitment to Automated Sample Processing In a major development within the life sciences and diagnostics sectors, QIAGEN N.V., headquartered in Venlo, Netherlands, and Germantown, Maryland, has achieved a significant milestone with the placement of its 4,000th QIAcube Connect instrument. This notable accomplis...
|
| Business Update
Published Thu, Sep 11 2025 3:52 AM UTC
QIAGEN Achieves CE-IVDR Certification for QIAstat-Dx Portfolio While Expanding Oncology Offerings Through Strategic Partnerships for MRD TestingIn a significant advancement for molecular diagnostics, QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has secured European CE-IVDR certification for its entire portfolio of QIAstat-Dx syndromic testing systems and panels. This e...
|
| Business Update
Published Fri, Jun 27 2025 11:57 AM UTC
A New Chapter for QIAGEN: Stephen Rusckowski Appointed Chairman of Supervisory Board In a significant reshuffle at the helm, QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leader in the life sciences industry, has announced the appointment of Stephen H. Rusckowski as Chairman of its Supervisory Board. The decision was made following the Annual General Meeting of ...
|
| Business Update
Published Mon, Jun 2 2025 8:29 PM UTC
In a significant stride towards bolstering its oncology diagnostics capabilities, QIAGEN (NYSE: QGEN Frankfurt Prime Standard: QIA) has recently announced the expansion of its portfolio focused on detecting minimal residual disease (MRD) in oncology through two strategic partnerships. These collaborations are set to accelerate the utilization of MRD testing in clinical studi...
|
| Business Update
Published Fri, May 23 2025 4:48 AM UTC
VENLO, Netherlands QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a front-runner in molecular testing solutions, is making strategic strides to enhance the landscape of oncology research and global health. Through notable partnerships, cutting-edge product launches, and upcoming technological advancements, this life sciences giant is steadfast in its mission to d...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
1.94 $ |
| Revenues (TTM) |
9.3 $
|
| Cash Flow (TTM) |
- |
| Cash |
4.77 $
|
| Book Value |
17.26 $
|
| Dividend (TTM) |
0.25 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
356,929 |
| Net
Income per Employee (TTM) |
74,540 |
| Receivable Turnover Ratio (TTM) |
5.05 |
| Inventory Turnover Ratio (TTM) |
2.73 |
| Asset Turnover Ratio (TTM) |
0.32 |
|
|
| Per Share |
|
| Earnings (TTM) |
1.94 $
|
| Revenues (TTM) |
9.3 $ |
| Cash Flow (TTM) |
- |
| Cash |
4.77 $
|
| Book Value |
17.26 $ |
| Dividend (TTM) |
0.25 $ |
|
|
| |
| Consumables and related revenues |
|
 92.23 % |
of total Revenue |
| Instruments |
|
10.5 % |
of total Revenue |
| Sample technologies |
|
32.5 % |
of total Revenue |
| Diagnostic solutions |
|
39.47 % |
of total Revenue |
| PCR Nucleic acid amplification |
|
15.19 % |
of total Revenue |
| Genomics NGS |
|
11.88 % |
of total Revenue |
| Other |
|
3.68 % |
of total Revenue |
| Reportable Segment |
|
102.73 % |
of total Revenue |
| Netherlands |
|
1.16 % |
of total Revenue |
| Total Americas |
|
53.4 % |
of total Revenue |
| United States |
|
49.08 % |
of total Revenue |
| Other Americas |
|
4.33 % |
of total Revenue |
| Europe Middle East and Africa |
|
35.03 % |
of total Revenue |
| Asia Pacific Japan and Rest of World |
|
14.29 % |
of total Revenue |
| |
On February 6 2025 the Qiagen N V provided following guidance
nnQIAGEN N.V. Reports Strong Q4 2024 Results Exceeding Expectationsnn
VENLO, The Netherlands — QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has released its financial results for the fourth quarter and the full year of 2024, highlighting robust growth that surpassed earlier projections. For Q4 2024, the company achieved net sales of $521 million, reflecting a 2% increase compared to the same period in 2023. Notably, when taking into account constant exchange rates (CER), sales amounted to $525 million, marking a 3% rise over the previous year and exceeding the company's guidance of at least $520 million in CER sales.
Core sales, which exclude discontinued products like NeuMoDx ...
|
|
|
3.65% 